TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03222622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib hydrochloride cream
Description: Apply topically twice daily for 12 consecutive weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib hydrochloride cream
Description: Apply topically twice daily for 12 consecutive weeks
Study: NCT02890459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery - Prize
Description: Men are entered in a lottery that offers a chance to win high-value prizes after testing for HIV at a community health campaign. Staff will emphasize that only those who come for HIV testing will be entered into the lottery and that not everyone will win a prize. Participants were informed at enrollment about the list of prizes and corresponding probabilities of winning them, in terms that are understandable to men with low numeracy (e.g., 1 in 20 rather than 5%). The probabilities of winning prizes varied between 1-5%, with higher value prizes having lower probability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed Incentive - Voucher
Description: A standard gain-framed incentive arm in which participants will be offered a voucher for coming for a repeat HIV test in the future.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed Incentive - Voucher
Description: A standard gain-framed incentive arm in which participants will be offered a voucher for coming for a repeat HIV test in the future.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Aversion - Deposit
Description: A loss-aversion framed incentive in which participants will be asked to voluntarily make a deposit that can be retrieved, with interest on the deposit, if they come for an HIV test in the future (i.e. for repeat testing)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Aversion - Deposit
Description: A loss-aversion framed incentive in which participants will be asked to voluntarily make a deposit that can be retrieved, with interest on the deposit, if they come for an HIV test in the future (i.e. for repeat testing)
Study: NCT03222622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib hydrochloride cream
Description: Apply topically twice daily for 12 consecutive weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Apply topically twice daily for 12 consecutive weeks
Study: NCT03034057

Intervention type: DRUG
Group type: OTHER
Intervention: Sayana Press
Description: Sayana Press in the Uniject injection system
Study: NCT04005287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WST-057 (4% pirenzepine) High Dose 4mL
Description: Topical Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Low Dose
Description: Topical Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo High Dose
Description: Topical Solution
Study: NCT05003778

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional equipment resistance training
Description: Participants will undergo 6 weeks of traditional equipment resistance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal equipment resistance training
Description: Participants will undergo 6 weeks of minimal equipment resistance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal equipment resistance training
Description: Participants will undergo 6 weeks of minimal equipment resistance training
Study: NCT02216890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD70A
Description: Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
Study: NCT03028467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165 Dose 1
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165 Dose 2
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165 Dose 3
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate capsule/tablet 8-16 mg per week is given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate capsule/tablet 8-16 mg per week is given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate capsule/tablet 8-16 mg per week is given orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate capsule/tablet 8-16 mg per week is given orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as liquid as sterile 0.9% sodium chloride solution and will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid tablet 5 mg per week is given orally.
Study: NCT01201928

Intervention type: DRUG
Intervention: Comparator administered in parent trial
Description: Comparator arm may be different for each parent trial, consisting of some sort of usual care for diabetes

Intervention type: DRUG
Intervention: Technosphere Insulin Inhalation Powder
Description: Pulmonary delivered inhaled insulin formulation containing human insulin and Technosphere Inhalation Powder (administered in parent trial)
Study: NCT00128414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine (for 6 months)
Description: colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients \<70 kg or intolerant to the highest dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets identical in colour, shape, and taste were provided in blister packs.
Study: NCT02257242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 I.V. on Day 1 of each cycle
Study: NCT03028467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid tablet 5 mg per week is given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid tablet 5 mg per week is given orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: Folic acid tablet 5 mg per week is given orally.
Study: NCT01463215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol
Description: Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
Study: NCT02564211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: one 50 mg tablet QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: one 50 mg tablet QD
Study: NCT02141035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-l-carnitine
Description: Those randomized to the treatment arm will receive the medication at 1 g tid for 60 days
Study: NCT02141035

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The control subjects will receive placebo tablets that are identical in appearance and taste to the active medication tid for 60 days
Study: NCT03106649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Before administration of spinal anesthesia, Echocardiography will be performed to determine the LVEDA. If the LVEDA is more than 10 square cms, the patient will be considered as volume replete and spinal anesthesia will be administered. If the LVEDA is less than 10 square cms, a fluid bolus of 250 ml of a balanced salt solution will be given and LVEDA reassessed. This will be repeated till the LVEDA is more than 10 square cms or fluid bolus has been given twice and still the LVEDA is less than 10 square centimeters, in which case phenylephrine 1-2µg/kg will be given before administering spinal anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment of spinal hypotension
Description: For treatment of spinal hypotension, in the event of hypotension(defined as a mean arterial pressure less than 60 mm Hg or decrease in mean arterial pressure of more than 20% from the baseline value) after spinal anesthesia, the LVEDA will be assessed. If more than 10 square centimeters, the patient will be considered volume replete and a vasopressor in the form of phenylephrine 1-2µg/kg will be given. If the LVEDA is less than 10 square centimeters, a volume bolus of 250ml will be given. On reassessment if the LVEDA is still less than 10 square centimeters the volume bolus can be repeated. In the event of hypotension persisting in spite of volume resuscitation, phenylephrine 1-2µg/kg will be given.
Study: NCT03895671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Induction phase (first three cycles)~- ponatinib: 45 mg/day orally continuously~Following the results of disease evaluation after 3 cycles:~* Cohort A: AP-CML If a CHR and complete cytogenetic response are obtained after 3 months, ponatinib will be decreased at 30mg/day. If CHR and/or CCyR are not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~* Cohort B: MBC-CML If a CHR is obtained during the induction phase, ponatinib daily dose will be reduced to 30 mg/day. If CHR is not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~Maintenance therapy:~Ponatinib will be decreased to 30 mg/day. During maintenance therapy, If a major molecular response is reached, ponatinib will be decreased to 15mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Induction phase (first three cycles)~- ponatinib: 45 mg/day orally continuously~Following the results of disease evaluation after 3 cycles:~* Cohort A: AP-CML If a CHR and complete cytogenetic response are obtained after 3 months, ponatinib will be decreased at 30mg/day. If CHR and/or CCyR are not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~* Cohort B: MBC-CML If a CHR is obtained during the induction phase, ponatinib daily dose will be reduced to 30 mg/day. If CHR is not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~Maintenance therapy:~Ponatinib will be decreased to 30 mg/day. During maintenance therapy, If a major molecular response is reached, ponatinib will be decreased to 15mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Induction phase (first three cycles), Following the results of disease evaluation after 3 cycles and Maintenance therapy:~- 5-azacitidine : 75 mg/m² subcutaneously day 1 to day 7, every 4 weeks~No dose modification of 5-Azacitidine is planned in both cohorts. Azacitidine may be stopped at 24 months in case of MR4 defined as 0.0032%\<MR4≤0.01%;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Induction phase (first three cycles), Following the results of disease evaluation after 3 cycles and Maintenance therapy:~- 5-azacitidine : 75 mg/m² subcutaneously day 1 to day 7, every 4 weeks~No dose modification of 5-Azacitidine is planned in both cohorts. Azacitidine may be stopped at 24 months in case of MR4 defined as 0.0032%\<MR4≤0.01%;
Study: NCT03669939

Intervention type: OTHER
Intervention: Communication Strategy
Description: Communication Strategy The intervention consists of a handbook that refers to the CDC Guidelines with tools and communication strategies that the PCP can use when assessing their patients who are on opioids. The Handbook will have a description of the Ohm-app and the information the PCP can retrieve from the dashboard in their medical record. They will also be provided a template to use when seeing the patient to use as guide and as documentation.

Intervention type: OTHER
Intervention: Standard of Care
Description: The standard information about the CDC Guidelines and no other information that is available through the study.
Study: NCT02257242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 I.V. on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 I.V. on Day 1 of each cycle
Study: NCT05003778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction training
Description: Participants will undergo 6 weeks of blood flow restriction training
Study: NCT02280148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy of Intravenous Anesthesia
Description: The dose of intravenous anesthesia drug and time was controlled by the anesthesiologist,endoscopists were responsible for gastroscopy or colonoscopy , nurses assisted endoscopists with biopsy.Each subject's initial dose of propofol were set at 2mg / kg, and were added properly by anesthesiologists additional according to the subjects' intraoperative sedation or surgical time.
Study: NCT03216720

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: * Cannulation: 24-F arterial cannula, 29/29 F dual-stage venous cannula, and aortic root vent-/cardioplegia cannula~* Grafting: pedicled left internal mammary artery, and no-touch~* saphenous vein graft Heparin and protamine doses assessed by HMS Plus® Hemostasis Management System~* Target activated coagulation time of \>400 seconds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: * Cannulation: 24-F arterial cannula, 29/29 F dual-stage venous cannula, and aortic root vent-/cardioplegia cannula~* Grafting: pedicled left internal mammary artery, and no-touch~* saphenous vein graft Heparin and protamine doses assessed by HMS Plus® Hemostasis Management System~* Target activated coagulation time of \>400 seconds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Miniaturized extracorporeal circulation
Description: * Centrifugal pump to reduce mechanical stress~* Circuit coated with biosurface to increase haemocompatibilty.~* Ante- and retrograde autologous priming and low-volume cardioplegia solution (intermittend cold modified Calafiore) to minimize haemodilution~* Collapsible soft-shell reservoir for blood volume management~* Cell-saving device~* Venous air removing device and electric clamp system to air embolism

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional extracorporeal circulation
Description: * Roller pump~* Circuit uncoated~* Hard-shell venous reservoir~* Intermittend cold blood Harefield cardioplegia
Study: NCT04130893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stimulation of G13 then G15
Description: Study participant randomized into arm A will undergo a stimulation of point G13 at session N°2, then stimulation of point G15 at session N°3.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stimulation of G15 then G13
Description: Study participant randomized into arm B will undergo a stimulation of point G15 at session N°2, then stimulation of point G13 at session N°3.
Study: NCT02649452

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vibration
Description: vibration will be given using whole body vibration machine. The subject will place both palms on top of the vibration platform with their knee supported on the ground. They need to apply as much pressure on the vibration platform by using their body weight. The whole body vibration machine will be set at the frequency of 30 Hz and the amplitude of 5 mm. They need to hold that position for 1 minute for 3 sets with 1 minute rest in between. The researcher will immediately stop this if the subjects feel dizziness and discomfort

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration
Description: vibration will be given using whole body vibration machine. The subject will place both palms on top of the vibration platform with their knee supported on the ground. They need to apply as much pressure on the vibration platform by using their body weight. The whole body vibration machine will be set at the frequency of 30 Hz and the amplitude of 5 mm. They need to hold that position for 1 minute for 3 sets with 1 minute rest in between. The researcher will immediately stop this if the subjects feel dizziness and discomfort
Study: NCT01030120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: etanercept 50mg BIW S.Q.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01125410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dequalinium chloride
Description: Vaginal tablet, 10mg, 1 tablet daily for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: vaginal cream, 2%, once daily for 7 days
Study: NCT01242631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10 mg orally per day.
Study: NCT05026151

Intervention type: OTHER
Intervention: Nutrition therapy according to ICU protocol
Description: The study aims a verifying adherence to the ICU nutrition protocol

Intervention type: OTHER
Intervention: Nutrition therapy according to ICU protocol
Description: The study aims a verifying adherence to the ICU nutrition protocol
Study: NCT00276406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Description: Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
Study: NCT01356862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PASIREOTIDE
Description: One INTRAMUSCULAR INECTION OF PASIREOTIDE 60 MG 10 TO 7 DAYS BEFORE SURGERY

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: ONE INJECTION OF PLACEBO 10 TO 7 DAYS BEFORE SURGERY
Study: NCT00682279

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: oral topotecan (SK&F-104864); lapatinib (GW572016)
Description: This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
Study: NCT02521857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet administered followed by consumption of 240 mL (8 ounces) of water at different timepoints
Study: NCT02908633

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: canaloplasty and phacoemulsification
Study: NCT03174626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WLSCC
Description: Briefly, WLSCC contents are as follows: Psychosocial skill 1: Increase objectivity and awareness of thoughts and feelings in a distressing situation and learning the technique of a log entry; Psychosocial skill 2: Evaluate the situation to decide whether to change one's reactions or to take actions; Psychosocial skill 3: Increase the positive and the sense of meaning in your life; Psychosocial skill 4: Deflection strategies; Psychosocial skill 5: Take action when action is called for; Psychosocial skill 6: Assertion; Psychosocial skill 7: Saying No; Psychosocial skill 8 : Communication; Psychosocial skill 9: Become a better listener; Psychosocial skill 10: Empathy.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: No training provided. After data collection period is over, participants have the option to receive the WLSCC training
Study: NCT02449811

Intervention type: DRUG
Intervention: Perindopril

Intervention type: DRUG
Intervention: Olmesartan

Intervention type: DRUG
Intervention: Amlodipine

Intervention type: DRUG
Intervention: Hydrochlorothiazide
Study: NCT00740753

Intervention type: DEVICE
Group type: OTHER
Intervention: Yttrium 90 (TheraSphere)
Description: Y-90 embedded glass microspheres
Study: NCT02908633

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: canaloplasty and phacoemulsification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: canaloplasty and phacoemulsification
Study: NCT01741298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHARMS
Description: Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
Study: NCT03633656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model predictive control
Description: Computer aided dose selection for the treatment of iron deficient anemia.
Study: NCT02280148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Driving Simulator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 2mg / kg
Study: NCT02300675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic education program
Study: NCT01205048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emervel Classic Lidocaine
Description: 20 mg/mL + 0.3% lidocaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm® Ultra
Description: 24mg/mL
Study: NCT03942237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-injection QLB(quadratus lumborum block)
Description: Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine is given immediately after the correct position of needle tip is verified.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Inject 0.4ml/kg saline between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose 0.4ml/kg 0.9% NS is given immediately after the correct position of the needle tip is verified